Clinical trials: Diffuse Intrinsic Pontine Glioma
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Diffuse Intrinsic Pontine Glioma
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of temsirolimus when given together with vorinostat and with or without radiation therapy in treating younger patients with newly diagnosed or progressive diffuse…
- Trial name
- NCT02420613
- Testing
- Radiation Therapy, Temsirolimus, Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
- Trial name
- CMD03DIPG (NCT06221553)
- Testing
- B7H3 specific CAR T cell with IL-7Ra signaling domain
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Diffuse Intrinsic Pontine Glioma
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive childhood brain tumor that, despite many past clinical trials, has never been shown to respond to chemotherapy.
- Trial name
- NCT02992015
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
ONC201 in Pediatric H3 K27M Gliomas
This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant…
- Trial name
- NCT03416530
- Testing
- Dordaviprone (ONC201)
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Diffuse Intrinsic Pontine Glioma, Glioma
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT02960230
- Testing
- K27M peptide, Nivolumab
- Where
- 15 sites in United States, Switzerland
- Volunteers
- 50 people
- Sponsor
- Sabine Mueller, MD, PhD
Diffuse Intrinsic Pontine Glioma, Medulloblastoma, Childhood, Recurrent
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
The aim of this study is to assess the safety and efficacy of AloCELYVIR, which consist in bone marrow-derived allogenic mesenchymal stem cells infected with an oncolytic Adenovirus, ICOVIR-5.
- Trial name
- AloCELYVIR (NCT04758533)
- Testing
- AloCELYVIR
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy.
- Trial name
- KONQUER (NCT04771897)
- Testing
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
Re-Irradiation of Progressive or Recurrent DIPG
This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
- Trial name
- NCT03126266
- Testing
- re-irradiation
- Where
- 18 sites in Australia, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- University of Calgary
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma…
- Trial name
- NCT05518838
- Testing
- OKN-007
- Where
- 9 sites in United States
- Sponsor
- Oblato, Inc.
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG
The primary objectives of this trial are to evaluate the safety and tolerability of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device and to determine the maximum tolerated dose (MTD) or recommended phase 2…
- Trial name
- NCT05123534
- Testing
- SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- SonALAsense, Inc.
Diffuse Intrinsic Pontine Glioma, Brainstem Glioma
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular…
- Trial name
- NCT01106794
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's National Research Institute
DIPG Brain Tumor, Diffuse Brainstem Glioma
Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma
F. 50y.o. 77kg, DS confirmed 18 Nov. 2022 Received treatment: 11 courses of TMZ (240mg) Radiotherapy 30 courses of 1.8Gr (total 54 Gr, TMZ 140 mg on RT). Bevacizumab intravenously -400 mg -0-14-28-42 (December-February 2023).
- Conditions
- DIPG Brain Tumor, Diffuse Brainstem Glioma, H3 K27M, H3 K28M
- Trial name
- TRIANGLE (NCT06439849)
- Testing
- S-Gboxin
- Sponsor
- Petrov, Andrey
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Oncology, DIPG
xPedite: A Study to Expedite DIPG and DMG Research
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external…
- Conditions
- Oncology, DIPG, DMG
- Trial name
- NCT06140719
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- xCures
Glioma
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG).
- Trial name
- PBTC-047 (NCT02717455)
- Testing
- LBH589
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717699
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717712
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma
Phase I Study of Marizomib + Panobinostat for Children With DIPG
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer
- Trial name
- DIPG (NCT04341311)
- Testing
- Marizomib, Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute